AUY922 (luminespib from Novartis), an HSP90 antagonist, suppresses in vitro cancer cell growth in a dose-dependent manner and is associated with a significantly reduced tumor volume (by 92% compared to that in untreated controls) [120]. The gene discussed is HSP90AA1; the disease is cancer.